newsfilter
← Latest News
PR Newswire·

Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference

  • Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will hold a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025, at 10:30 a.m. ET in New York, NY.
  • The event will be live-streamed \& replayed via the "Events & Presentations" section of the company's investor website.
  • Karyopharm is a commercial-stage pharmaceutical company focused on oral compounds targeting nuclear export dysregulation.
  • The company's lead product, XPOVIO® (selinexor), is an oral exportin 1 (XPO1) inhibitor approved in the U.S. for three oncology indications.
  • XPOVIO® has received regulatory approvals in 50 ex-U.S. territories, including the EU, the UK (as NEXPOVIO®), \& China.
  • The company's pipeline targets multiple myeloma, endometrial cancer, myelofibrosis, \& diffuse large B-cell lymphoma (DLBCL).